Ireland's R&D drugmakers cut over 600 branded ex-patent product prices
An agreement between the Irish Pharmaceutical Healthcare Association and the Health Service Executive has resulted in the price of many leading medicines being reduced in two phases, by 35% over the last 22 months, with the second effective from January 1.
In March 2007, patients saw a reduction of up to 20% in the price of nearly 600 different packs of medicines on the Irish market, the IPHA explained. Among the affected products were many high-volume, long-established, post-patent drugs. The second phase of price reductions, involves a further 15% price cut.
45 additional drugs added to price-cut scheme
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze